Tetraphase Pharmaceuticals (TTPH) Cut to Market Perform at BMO Capital Markets

Tetraphase Pharmaceuticals (NASDAQ:TTPH) was downgraded by stock analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating in a report issued on Wednesday. They currently have a $24.00 price objective on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the company. HC Wainwright decreased their price objective on Tetraphase Pharmaceuticals from $17.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday. B. Riley began coverage on Tetraphase Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $11.00 price objective on the stock. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 12th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $8.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Wednesday. Finally, BidaskClub lowered Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $10.39.

Tetraphase Pharmaceuticals (TTPH) traded down $3.28 during trading on Wednesday, reaching $2.15. The company’s stock had a trading volume of 16,821,900 shares, compared to its average volume of 461,216. The firm has a market capitalization of $110.93, a price-to-earnings ratio of -0.75 and a beta of 2.28. Tetraphase Pharmaceuticals has a 12 month low of $2.10 and a 12 month high of $9.93.

In other Tetraphase Pharmaceuticals news, Director L Patrick Gage purchased 3,880 shares of the firm’s stock in a transaction on Wednesday, November 29th. The shares were purchased at an average cost of $6.45 per share, with a total value of $25,026.00. Following the purchase, the director now owns 38,880 shares in the company, valued at $250,776. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jacques Dumas sold 8,750 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total value of $54,425.00. Following the completion of the sale, the insider now directly owns 8,750 shares in the company, valued at $54,425. The disclosure for this sale can be found here. 5.50% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of TTPH. SG Americas Securities LLC acquired a new stake in Tetraphase Pharmaceuticals in the 3rd quarter worth about $107,000. Brighton Jones LLC acquired a new stake in Tetraphase Pharmaceuticals in the 3rd quarter worth about $108,000. Voya Investment Management LLC boosted its stake in Tetraphase Pharmaceuticals by 17.8% in the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 3,104 shares during the last quarter. Virtu KCG Holdings LLC acquired a new stake in Tetraphase Pharmaceuticals in the 2nd quarter worth about $147,000. Finally, Ameriprise Financial Inc. acquired a new stake in Tetraphase Pharmaceuticals in the 2nd quarter worth about $162,000. 58.28% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Tetraphase Pharmaceuticals (TTPH) Cut to Market Perform at BMO Capital Markets” was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2018/02/14/tetraphase-pharmaceuticals-ttph-cut-to-market-perform-at-bmo-capital-markets.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply